Pharmaceutical industry – Page 54
-
Business
Pfizer to pay $250m for Nexium
AstraZeneca has sold rights to an over the counter version of its heartburn tablets
-
Business
Elan spins off drug discovery
The new company will be called Neotope Biosciences and focus on chronic degenerative diseases
-
Business
DSM buys into cattle supplements
The company has struck a EUR465 million deal to acquire Tortuga
-
Business
Bapineuzunab dropped
Development for the Alzheimer’s treatment stopped after clinical tests
-
BusinessIrish pharma exports tumble
Seven of the top 10 drugs going off patent between 2011 and 2014 are produced in Ireland
-
Business
New cystic fibrosis drug in EU
Ivacaftor works by helping defective proteins function more normally
-
Business
Drugs top EU counterfeit imports
In 2011, medicines topped the list of fake products entering the EU
-
Business
GSK secures $3.6bn HGS deal
GlaxoSmithKline is set to buy Human Genome Sciences for $3.6 billion
-
BusinessObesity drug approved in US
Qsymia from Vivus joins Belviq in a lucrative part of the pharma industry
-
Business
First HIV drug approved as prevention
Truvada tablets can reduce the risk of infection for an HIV-negative person
-
Business
Drug spending to hit $1.2tn in 2016
Growth is expected to bottom out at 3–4% for 2012 and then rise to 5–7% for 2016
-
Business
GSK drug shines in HIV trial
HIV–Aids drug candidate dolutegravir outperformed Atripla tablets in Phase III
-
News
China targets patented drugs with law change
Domestic drug companies can apply for licences to produce patented drugs when public health overrides intellectual property considerations
-
BusinessInterview: EMA head Guido Rasi
Guido Rasi, head of the European Medicines Agency, wants to see greater transparency in drug development
-
Business
Is Sanofi cutting jobs in France?
News outlets are reporting plans to cut 1000-2000 employees in France
-
Business
BMS and AstraZeneca buy Amylin for $7bn
Two pharma giants have teamed up to buy US biotech Amylin, responsible for the Byetta and Bydureon anti-diabetes brands
-
Business$3bn GSK fine sets new industry record
The fine relates to off label marketing and is the largest payment of its kind ever made by a drug company
-
News
FDA green lights new obesity drug
Agency approval for prescription only obesity drug is first for 13 years
-
Business
Roche rapped for side-effect reporting failure
European medicines regulator names and shames Swiss giant for not disclosing 80,000 instances of potential adverse drug reactions
-
Business
Roche cuts 1000 jobs with US R&D site closure
Streamlining strategy will see oncology and virology research moved to Switzerland and Germany